Serum Sialyl Lewisx and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer

Lung Cancer

Volumn 58, Issue 3, 2007, Pages 369-375

  Mizuguchi, Shinjiro ^a,b   Nishiyama, Noritoshi ^a   Iwata, Takashi ^a   Nishida, Tatsuya ^a   Izumi, Nobuhiro ^a   Tsukioka, Takuma ^a   Inoue, Kiyotoshi ^b   Uenishi, Takahiro ^c   Wakasa, Kenichi ^c   Suehiro, Shigefumi ^c  

^a OSAKA CITY UNIVERSITY HOSPITAL   (Japan)

^b Bell Land General Hospital   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Combination; Cytokeratin 19 fragment; Early stage; Lung cancer; Recurrence; Sialyl Lewisx; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; SIALYL LEWIS X ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KERATIN-19; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGOSACCHARIDES; PEPTIDE FRAGMENTS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 35748940008     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.07.002     Document Type: Article

References (48)

1. Nesbitt J.C., Putnam Jr. J.B., Walsh G.L., Roth J.A., and Mountain C.F. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 60 (1995) 466-472
2. D'Amico T.A., Aloia T.A., Moore M.B., Conlon D.H., Herndon II J.E., Kinch M.S., et al. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg 72 (2001) 1144-1148
3. Brundage M.D., Davies D., and Mackillop W.J. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122 (2002) 1037-1057
4. Tumour markers in lung cancer: EGTM recommendations. European Group on Tumour Markers. Anticancer Res 1999;19:2817-9.
5. Ando S., Kimura H., Iwai N., Kakizawa K., Shima M., and Ando M. The significance of tumour markers as an indication for mediastinoscopy in non-small cell lung cancer. Respirology 8 (2003) 163-167
6. Takamochi K., Nagai K., Suzuki K., Yoshida J., Ohde Y., and Nishiwaki Y. Clinical predictors of N2 disease in non-small cell lung cancer. Chest 117 (2000) 1577-1582
7. Diez M., Torres A., Maestro M.L., Ortega M.D., Gomez A., Pollan M., et al. Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer 73 (1996) 1248-1254
8. Gaspar M.J., Diez M., Rodriguez A., Ratia T., Martin Duce A., Galvan M., et al. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer. Anticancer Res 23 (2003) 3427-3432
9. Brechot J.M., Chevret S., Nataf J., Le Gall C., Fretault J., Rochemaure J., et al. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 33 (1997) 385-391
10. Takada M., Masuda N., Matsuura E., Kusunoki Y., Matui K., Nakagawa K., et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer 71 (1995) 160-165
11. Pujol J.L., Molinier O., Ebert W., Daures J.P., Barlesi F., Buccheri G., et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 90 (2004) 2097-2105
12. Moro D., Villemain D., Vuillez J.P., Delord C.A., and Brambilla C. CEA, CYFRA21-1 and SCC in non-small cell lung cancer. Lung Cancer 13 (1995) 169-176
13. Stieber P., Hasholzner U., Bodenmüller H., Nagel D., Sunder-Plassmann L., Dienemann H., et al. CYFRA 21-1. A new marker in lung cancer. Cancer 72 (1993) 707-713
14. Sugama Y., Kitamura S., Kawai T., Ohkubo A., Hasegawa S., Kuriyama T., et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res 85 (1994) 1178-1184
15. Muley T., Dienemann H., and Ebert W. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res 24 (2004) 1953-1956
16. Muley T., Dienemann H., and Ebert W. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. Anticancer Res 23 (2003) 4085-4093
17. Sawabata N., Ohta M., Takeda S., Hirano H., Okumura Y., Asada H., et al. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg 74 (2002) 174-179
18. Sakao Y., Tomimitsu S., Takeda Y., Natsuaki M., and Itoh T. Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma. Eur J Cardiothorac Surg 25 (2004) 520-522
19. Suzuki K., Nagai K., Yoshida J., Moriyama E., Nishimura M., Takahashi K., et al. Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg 67 (1999) 927-932
20. Nishida K., Yamamoto H., Ohtsuki T., Matsuba M., Mukai S., Naito Y., et al. Elevated tissue concentrations of sialyl Lex-i in cancerous tissues compared with those in noncancerous tissues of various organs. Cancer 68 (1991) 111-117
21. Imada T., Rino Y., Takahashi M., Hatori S., Shiozawa M., Amano T., et al. Serum CA 19-9, SLX, STN and CEA levels of the peripheral and the draining venous blood in gastric cancer. Hepatogastroenterology 46 (1999) 2086-2090
22. Nakagoe T., Sawai T., Tsuji T., Jibiki M.A., Nanashima A., Yamaguchi H., et al. Predictive factors for preoperative serum levels of Sialy Lewis(x), Sialyl Lewis(a) and sialyl Tn antigens in gastric cancer patients. Anticancer Res 22 (2002) 451-458
23. Ikeda Y., Mori M., Kajiyama K., Haraguchi Y., Sasaki O., and Sugimachi K. Immunohistochemical expression of sialyl Tn, Sialyl Lewis a, Sialyl Lewis a-b-, and Sialyl Lewis x in primary tumor and metastatic lymph nodes in human gastric cancer. J Surg Oncol 62 (1996) 171-176
24. Nakagoe T., Kusano H., Hirota M., Fukushima K., Hiratani K., Hara K., et al. Serological and immunohistochemical studies on sialylated carbohydrate antigens in colorectal carcinoma. Gastroenterol Jpn 26 (1991) 303-311
25. Nakagoe T., Fukushima K., Hirota M., Kusano H., Ayabe H., Tomita M., et al. Immunohistochemical expression of sialyl Lex antigen in relation to survival of patients with colorectal carcinoma. Cancer 72 (1993) 2323-2330
26. Tanaka K., Togo S., Nanko M., Ishikawa T., Ichikawa Y., Yamaoka H., et al. Sialyl Lewis X expression in vascular permeating lesions as a factor for predicting colorectal cancer metastasis. Hepatogastroenterology 46 (1999) 875-882
27. Yamaguchi A., Goi T., Seki K., Ohtaki N., Maehara M., Kobayashi T., et al. Clinical significance of combined immunohistochemical detection of CD44v and sialyl LeX expression for colorectal cancer patients undergoing curative resection. Oncology 55 (1998) 400-403
28. Ogawa J., Tsurumi T., Yamada S., Koide S., and Shohtsu A. Blood vessel invasion and expression of Sialyl Lewisx and proliferating cell nuclear antigen in stage I non-small cell lung cancer. Relation to postoperative recurrence. Cancer 73 (1994) 1177-1183
29. Tsumatori G., Ozeki Y., Takagi K., Ogata T., and Tanaka S. Relation between the serum E-selectin level and the survival rate of patients with resected non-small cell lung cancers. Jpn J Cancer Res 90 (1999) 301-307
30. Kawai T., Suzuki M., Kase K., and Ozeki Y. Expression of carbohydrate antigens in human pulmonary adenocarcinoma. Cancer 72 (1993) 1581-1587
31. Mizuguchi S., Inoue K., Iwata T., Nishida T., Izumi N., Tsukioka T., et al. High serum concentrations of Sialyl Lewis(x) predict multilevel N2 disease in non-small-cell lung cancer. Ann Surg Oncol 13 (2006) 1010-1018
32. Satoh H., Ishikawa H., Yamashita Y.T., Takahashi H., Ishikawa S., Kamma H., et al. Predictive value of preoperative serum Sialyl Lewis X-i antigen levels in non-small cell lung cancer. Anticancer Res 18 (1998) 2865-2868
33. Oyama T., Kawamoto T., Matsuno K., Osaki T., Matsumoto A., Isse T., et al. A case-case study comparing the usefulness of serum trace elements (Cu, Zn and Se) and tumor markers (CEA, SCC and SLX) in non-small cell lung cancer patients. Anticancer Res 23 (2003) 605-612
34. Satoh H., Ishikawa H., Kamma H., Yamashita Y.T., Takahashi H., Ohtsuka M., et al. Serum Sialyl lewis X-i antigen levels in non-small cell lung cancer: correlation with distant metastasis and survival. Clin Cancer Res 3 (1997) 495-499
35. WHO. Histological typing of lung and pleural tumours. In: Travis W.D., Colby T.V., Corrin B., Shimosato Y., and Brambilla E. (Eds). Collaboration with pathologists in 14 countries. 3rd ed. (1999), World Heath Organization, Geneva
36. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
37. Naruke T., Suemasu K., and Ishikawa S. Surgical treatment for lung cancer with metastasis to mediastinal lymph nodes. J Thorac Cardiovasc Surg 71 (1976) 279-285
38. Martini N., and Flehinger B.J. The role of surgery in N2 lung cancer. Surg Clin North Am 67 (1987) 1037-1049
39. Metz C.E., Herman B.A., and Roe C.A. Statistical comparison of two ROC-curve estimates obtained from partially-paired datasets. Med Decis Making 18 (1998) 110-121
40. Metz C.E., Herman B.A., and Shen J.H. Maximum likelihood estimation of receiver operating characteristic (ROC) curves from continuously-distributed data. Stat Med 17 (1998) 1033-1053
41. Bevilacqua M.P., Pober J.S., Mendrick D.L., Cotran R.S., and Gimbrone Jr. M.A. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 84 (1987) 9238-9242
42. Lowe J.B., Stoolman L.M., Nair R.P., Larsen R.D., Berhend T.L., and Marks R.M. ELAM-1-dependent cell adhesion to vascular endothelium determined by a transfected human fucosyltransferase cDNA. Cell 63 (1990) 475-484
43. Phillips M.L., Nudelman E., Gaeta F.C., Perez M., Singhal A.K., Hakomori S., et al. ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science 250 (1990) 1130-1132
44. Walz G., Aruffo A., Kolanus W., Bevilacqua M., and Seed B. Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science 250 (1990) 1132-1135
45. Takada A., Ohmori K., Takahashi N., Tsuyuoka K., Yago A., Zenita K., et al. Adhesion of human cancer cells to vascular endothelium mediated by a carbohydrate antigen, Sialyl Lewis A. Biochem Biophys Res Commun 179 (1991) 713-719
46. Berg E.L., Magnani J., Warnock R.A., Robinson M.K., and Butcher E.C. Comparison of L-selectin and E-selectin ligand specificities: the L-selectin can bind the E-selectin ligands sialyl Le(x) and sialyl Le(a). Biochem Biophys Res Commun 184 (1992) 1048-1055
47. Bresalier R.S., Ho S.B., Schoeppner H.L., Kim Y.S., Sleisenger M.H., Brodt P., et al. Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterology 110 (1996) 1354-1367
48. x in non-small cell lung cancer. Ann Thorac Surg 83 (2007) 216-221